07:00 , Aug 22, 2016 |  BC Week In Review  |  Clinical News

Amphora: Phase I started

Evofem began a double-blind, U.S. Phase I trial to compare 3, 4, and 5 g Amphora vaginal gel vs. a hydroxyethylcellulose placebo gel or no treatment in about 100 healthy female volunteers. Evofem Inc. ,...
08:00 , Jan 15, 2007 |  BC Week In Review  |  Company News

Amphora management update

Amphora Discovery Corp. , Research Triangle Park, N.C.   Business: Chemistry, Genomics, Supply/Service   Promoted: William Janzen to president and COO from VP of operations and CTO  ...
08:00 , Jan 15, 2007 |  BC Week In Review  |  Company News

Amphora, Genentech deal

DNA acquired a cancer program from Amphora, including preclinical drug candidates for an undisclosed target. Financial terms were not disclosed. Amphora Discovery Corp. , Los Altos, Calif.   Genentech Inc. (DNA), South San Francisco, Calif....
08:00 , Feb 27, 2006 |  BC Week In Review  |  Company News

Amphora, Nanosyn Inc. deal

Nanosyn will provide chemistry services to Amphora to assist in the design and synthesis of small molecules. Amphora will own resulting compounds. Nanosyn will receive an upfront fee and research funding and is eligible for...
07:00 , May 2, 2005 |  BioCentury  |  Finance

MPM's portfolio

MPM's portfolio...
07:00 , Apr 11, 2005 |  BC Week In Review  |  Company News

Xenome board of directors update

Xenome Ltd. , Brisbane, Australia   Business: Neurology   Appointed: Peter Myers, VP of chemical sciences at Structural GenomiX Inc.; and Jeff Riley, VP of finance and corporate development at Amphora Discovery Corp.  ...
08:00 , Jan 17, 2005 |  BC Week In Review  |  Company News

Amphora Discovery Inc., J&J deal

Amphora and JNJ's Ortho-McNeil Pharmaceutical Inc. unit partnered to discover and develop treatments for inflammatory diseases. Ortho-McNeil received exclusive rights to Amphora's compounds against an undisclosed inflammation target and to compounds discovered during the collaboration....
08:00 , Jan 10, 2005 |  BC Extra  |  Company News

Amphora, JNJ inflammation deal

Amphora (Durham, N.C.) and Johnson & Johnson (JNJ) partnered to discover and develop treatments for inflammatory diseases. JNJ received exclusive rights to Amphora's compounds against an undisclosed inflammation target and to compounds discovered during the...
08:00 , Dec 8, 2004 |  BC Extra  |  Financial News

Amphora raises $20 million

Chemistry and genomics company Amphora (Durham, N.C.) raised $20 million in a series C round led by 3i. Other investors included Novartis Venture Fund; Aventis Capital; ARCH; MPM; Venrock; and Versant. Amphora is using its...
07:00 , Aug 30, 2004 |  BC Week In Review  |  Company News

Amphora Discovery Inc. board of directors update

Amphora Discovery Inc. , Durham, N.C.   Business: Chemistry, Genomics   Appointed: Peter Savas, managing partner at Tug Hill Partners LLC, as chairman  ...